Stay updated with breaking news from Benjamin Rome. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The year after people receive concurrent flu and shingles shots, flu shots dip, which could mean that people are incorrectly associating adverse effects with the flu vaccine, researchers suggest.
E-Mail WHO Benjamin Rome, MD, Instructor of Medicine at Harvard Medical School and researcher in the Program On Regulation, Therapeutics, And Law (PORTAL) in the Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital; corresponding author of a paper published in WHAT When drug manufacturers raise the list price for brand-name prescription drugs, do patients' out-of-pocket costs rise too? A new study published in JAMA Network Open by Dr. Benjamin Rome and colleagues in the Brigham's Division of Pharmacoepidemiology and Pharmacoeconomics finds that more than ...
Despite Drug Industry Claims, Higher List Prices Do Mean Higher Out-of-Pocket Costs for Many Patients Share Filed to:benjamin rome copaymentdaraprimdrug pricinghealth medical pharmahealth scienceshealthcare reform in the united statesmartin shkrelimedicaremedication costspharmaceutical industrypharmaceuticals policypharmacypharmacy benefit managementprescription drugturing pharmaceuticalsu s healthcare A pharmacy technician filling out a prescription of Levoxyl at the Rosemont Pharmacy in Portland, Maine on January 18, 2006 (Photo: Joe Raedle, Getty Images) To sign up for our daily newsletter...
Rising out-of-pocket drug costs linked to increase in brand-name prices By (0) Rising out-of-pocket drug costs for consumers are linked with increases in charges for brand-name drugs, a new study has found. File Photo by Billie Jean Shaw/UPI May 4 (UPI) -- When drug manufacturers raise prices for brand-name prescription medications, consumers see a corresponding increase in out-of-pocket costs above and beyond their insurance co-pays, an analysis published Tuesday by JAMA Network Open found. Increasing the "list price" of a brand-name drug by 17% rose the "net price" -- the cost after co-pa...